Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel

The European Commission has officially approved Pfizer's (NYSE: PFE) drug Vyndaqel as a treatment for transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM), a disease characterized by the buildup of misfolded TTR protein in the heart. Vyndaqel is designed to stabilize the protein and keep it from misfolding.